Ann: Acrux presents at BioTrinity-ACR.AX, page-12

This is what WilsonHTM had to say about ACR this morning...

We like the approach management is taking to rebuilding Acrux’s portfolio approach to its drug development business. While concerns surrounding AXIRON (testosterone market decline, potential for generic competition) are likely to continue, the outlook for royalty earnings over the medium term is sufficient to support dividends and the modest R&D investments building clinical asset value. Acrux has remained very active on its development programs, nominating three US generic projects. Some of Acrux’s higher value programs (eg onychomycosis) may also be nearing the point of nominating lead formulations to take into pre-clinical and clinical studies. We expect the tax-exempt nature of Acrux’s 9.4% dividend yield to support the share price while the company builds out its next phase of growth. Upgrade to SPECULATIVE BUY. Revised price target is 74cps.

Now the analyst don't just pull these comments out of the blue - they get them for talking directly to management... a luxury  retail investors don't have....